跳至主要内容
临床试验/NL-OMON53259
NL-OMON53259招募中不适用

Quality of life, Survival, COmorbidities, and Pharmacoeconomics in Elderly patients with Acute Myeloid Leukemia - QSCOPE-AM

Medisch Centrum Leeuwarden0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
65 至 99(—)

入选标准

  • Patient is diagnosed with de novo AML [ICD-10 = C92]
  • Patient is treated in the Medical Centre Leeuwarden
  • Age upon diagnosis >= 65 years
  • Patient is classified as *ineligible for intensive chemotherapy* by the list
  • 1 of the Ferrara criteria or by consideration from the practising haematologist
  • Patient receives treatment in the form of a HMA combination regimen
  • Patient provides a signed Informed Consent Form

排除标准

  • Bonemarrow analysis did not confirm AML
  • Patients diagnosed with APL (t(15;17), WHO 2016) [ICD-10 = C92.4]
  • Patients diagnosed with AMML (AML M4 / AML-M4eos) [ICD-10 = C92.5]
  • Patients diagnosed with AMBL/AMCL (AML M5 / M5a / M5b) [ICD-10 = C93]

研究者

发起方
Medisch Centrum Leeuwarden

相似试验